← Markets

Mesa Laboratories, Inc.

MLAB · NASDAQ

Market closed$97.94$-1.50 (-1.51%)After hours $96.98 · -0.98%

Chart data is refreshing.

Key statistics

Previous close$97.94
Open$97.10
Day high$100.87
Day low$96.38
52-week high$113.99
52-week low$55.45
Market cap541.11M
Volume189.61K
Average volume197.31K
P/E ratio9.88
Forward P/E—
EPS9.91
Dividend yield+0.65%

Market context

Why it moved

MLAB shares declined as institutional analysis identified a high-conviction short setup with significant downside potential, weighing on near-term sentiment amid a mid-term weak bias despite the stock's longer-term strength context.

CoingabbarStocktradersdailyInstagramYelpYahoo Finance

What is happening

Recent company-specific developments and publisher coverage.

July 16, 2026Mesa Laboratories surged over 5% on July 16, closing near session highs as the broader healthcare sector rallied sharply alongside a UnitedHealth earnings beat that lifted sentiment across medical equipment and services names. UNH's Q2 results — which topped Wall Street estimates on both revenue and profit and prompted an upward revision to full-year guidance — helped reverse recent sector weakness and drove the Healthcare Services & Equipment industry up roughly 2.7% on the day, providing a meaningful tailwind for smaller-cap medtech names like Mesa Labs. The move came amid a constructive macro backdrop, with softer-than-expected June PPI data reinforcing hopes the Fed can hold rates steady, a positive for capital-intensive healthcare and life sciences companies.

5.0275

July 10, 2026Mesa Laboratories closed modestly higher, supported by a recent valuation case from analysts suggesting shares trade at a ~31% discount to estimated fair value based on cash flows, with earnings expected to grow ~31% annually. Adding to investor interest, Long Path — an institutional fund — filed an amended 13G/A disclosing an 8.6% passive stake (477,126 shares), reaffirming meaningful institutional conviction in the small-cap life sciences tools company. The broader healthcare sector saw some softness, with the XLV ETF drifting lower, though Mesa's quality control and sterilization products business remains a relative niche play heading into Q2 earnings season.

0.2306

July 9, 2026Mesa Laboratories surged over 4% in above-average volume — more than 1.7x its typical daily turnover — as healthcare stocks continued their multi-week outperformance over technology, with the sector ETF (XLV) logging a second consecutive week of market-leading gains. A quarterly dividend declaration of $0.16 per share, payable September 15, reinforced the company's capital return profile, while Q3 revenue growth of ~3.6% year-over-year signals steady operational momentum in its quality control and life science tools business.

4.4111

July 7, 2026Mesa Laboratories tumbled over 6% after its Board declared a routine quarterly dividend of $0.16 per share — a figure that may have disappointed investors expecting more meaningful capital returns given the company's Q3 2026 revenue of $65.1M, a modest 3.64% year-over-year increase. The sharp decline stands in stark contrast to the broader healthcare sector (XLV), which closed near 52-week highs and has been one of the market's top-performing sectors in recent weeks, suggesting the selloff was driven by company-specific concerns rather than sector headwinds.

-6.2402

July 6, 2026Mesa Laboratories closed down nearly 3%, underperforming a broadly softer healthcare sector (XLV fell on the day) as investors digested a Q2 2026 earnings report that included a heavy GAAP EPS miss of -$0.75 amid operational challenges. The company simultaneously declared its regular quarterly dividend of $0.16 per share payable September 15, a signal of capital return continuity, but the dividend announcement did little to offset concern over the earnings shortfall and ongoing pressures facing the healthcare equipment space.

-2.8236

July 1, 2026Mesa Laboratories surged nearly 5% in regular trading and extended gains further in after-hours, climbing an additional ~4% to around $108, despite reporting a significant EPS miss in its Q1 2026 results — a loss of $0.75 per share — just days earlier. The rebound appears tied to broader healthcare sector momentum, as investors rotated into defensive healthcare names amid tech volatility and US-Iran geopolitical tensions; the XLV healthcare ETF has been one of the strongest-performing sectors recently. With MLAB trading well above its prior close of $99.55 and volume near average, investors may be reassessing the severity of the earnings miss or positioning ahead of further sector strength.

4.8619

June 29, 2026Mesa Laboratories declined nearly 3% on Monday, underperforming the broader healthcare sector as the XLV ETF closed near its 52-week high amid a market-wide relief rally driven by U.S.-Iran ceasefire news. While healthcare broadly outperformed tech — posting a record weekly return relative to the S&P 500 last week — Mesa Labs bucked the sector's strength. Peer medical device maker CONMED also fell sharply after a BofA downgrade citing growth concerns, reflecting broader pressure on smaller medical equipment names. Technical signals show near-term support around $98.68, with analysts flagging mid-term weakness despite a longer-term bullish bias.

-2.8217

June 26, 2026Mesa Laboratories surged over 4% after recovering from a prior week's 6.5% pullback, outperforming a broadly positive healthcare sector — with the XLV ETF near 52-week highs and Eli Lilly hitting an all-time high. Investor focus remains on the company's ongoing leadership transition following the departure of CEO Gary Owens and a disappointing Q4 that saw Biological Products Division core revenue fall 32% due to export-control shipping delays. Despite the setbacks, Jefferies raised its price target to $130 from $115 while maintaining a Buy rating, citing the stock's apparent undervaluation (InvestingPro Fair Value: $112.51) and a compelling PEG ratio of 0.17. Recent insider share sales by the CFO, SVP of Operations, and CAO were routine tax-cover transactions tied to RSU/PSU vestings under pre-arranged 10b5-1 plans, not discretionary sells.

4.3505

Quiver Quantitative · July 6, 2026Mesa Laboratories Declares Regular Quarterly Dividend of $0.16 per ShareQuiver Quantitative · May 5, 2026Mesa Laboratories, Inc. Scheduled to Release Q4 and Fiscal Year 2026 Financial Results on May 27, 2026Seeking Alpha · March 10, 2026Mesa Laboratories: Hard To Set The Right Diagnosis (NASDAQ:MLAB)Stock Titan · March 9, 2026Mesa leadership shift: Gary Owens exits, Siddhartha Kadia takes CEO role
Mt Newswire · July 6, 2026Mesa Laboratories Keeps Quarterly Dividend at $0.16 per Share, Payable Sept. 15 to Shareholders of Record Aug. 31
Benzinga · May 27, 2026Mesa Laboratories Q4 Adj. EPS $3.30 Beats $0.34 Estimate, Sales $63.724M Miss $65.171M Estimate
Mt Newswire · March 9, 2026Mesa Laboratories Names Siddhartha Kadia as President and CEO
Benzinga · March 9, 2026Mesa Laboratories President, CEO Gary Owens Stepping Down, Effective April 12; Siddhartha Kadia Appointed Successor
Benzinga · February 4, 2026Wells Fargo Maintains Equal-Weight on Mesa Laboratories, Raises Price Target to $94
Benzinga · February 3, 2026Mesa Laboratories Earnings Review: Q3 Summary
Benzinga · February 3, 2026Mesa Laboratories Q3 Earnings Report: What Investors Need to Know
Benzinga · February 3, 2026Mesa Laboratories Earnings Report: Q3 Overview

Peers

S&P 500SPX · $7,457.69-1.01%Vishay Precision Group, Inc.VPG · $106.01+5.31%Cognex CorporationCGNX · $64.22+0.52%Coherent, Inc.COHR · $286.00+3.26%Sotera Health CompanySHC · $17.75-2.85%Stevanato Group S.p.A.STVN · $19.37-3.63%Repligen CorporationRGEN · $147.00-1.04%Qiagen N.V.QGEN · $41.16-0.84%Agilent Technologies, Inc.A · $131.80-3.16%Bio-Rad Laboratories, Inc.BIO · $304.36+1.12%Bruker CorporationBRKR · $57.70-2.62%Danaher CorporationDHR · $204.15-0.42%